Angiogenesis is the biological process by which new blood vessels form from pre-existing ones. While this process is essential for normal growth and tissue repair, it also plays a critical role in cancer development. Solid tumors cannot grow beyond a very small size without access to oxygen and nutrients supplied by blood vessels. To overcome this limitation, cancer cells actively stimulate the formation of new vessels in their surrounding tissue.
Tumor-induced angiogenesis not only supports tumor growth but also facilitates invasion and metastasis by providing routes for cancer cells to enter the bloodstream. Moreover, the blood vessels formed in tumors are structurally and functionally abnormal, which influences drug delivery and treatment response.
In this article, we will first explain the biological basis of angiogenesis, then explore how tumors activate this process, discuss the consequences of abnormal tumor vasculature, and finally examine how angiogenesis is targeted in cancer therapy.
What Is Angiogenesis?
Definition and Basic Steps of Angiogenesis
Angiogenesis refers to the formation of new capillaries from existing blood vessels. It is a tightly regulated, multi-step process that involves coordinated actions of endothelial cells, which line the inner surface of blood vessels.
The main steps include:
- Endothelial cell activation in response to growth factors
- Degradation of the basement membrane by proteolytic enzymes
- Migration of endothelial cells toward the angiogenic signal
- Proliferation of endothelial cells to extend the new vessel sprout
- Tube formation and lumen development
- Recruitment of supporting cells (pericytes) for vessel stabilization
In healthy tissues, these steps are carefully controlled and stop once sufficient blood supply is restored.
Physiological Roles of Angiogenesis
Angiogenesis is not inherently pathological. It is essential for several normal physiological processes, including:
- Embryonic development, where expanding tissues require rapid vascularization
- Wound healing, allowing delivery of immune cells and nutrients to damaged tissue
- Reproductive processes, such as formation of the uterine lining during the menstrual cycle
- Placental development, ensuring oxygen and nutrient exchange between mother and fetus
In these contexts, angiogenesis is temporary and self-limiting, returning to baseline once tissue demands are met.
Angiogenesis vs Vasculogenesis
Although often confused, angiogenesis and vasculogenesis are distinct processes:
- Angiogenesis forms new vessels from existing ones through endothelial sprouting.
- Vasculogenesis involves the formation of blood vessels from endothelial progenitor cells, mainly during embryonic development.
In cancer, angiogenesis is the dominant mechanism of vascular expansion. However, some evidence suggests that circulating progenitor cells may also contribute to tumor vasculature, particularly in highly aggressive tumors.
Molecular Mechanisms of Tumor-Induced Angiogenesis
Hypoxia as the Main Trigger
As tumors grow, cells located far from existing blood vessels experience low oxygen levels (hypoxia). Hypoxia is the strongest stimulus for angiogenesis in solid tumors.
Under normal oxygen conditions, the transcription factor HIF-1α (hypoxia-inducible factor-1 alpha) is rapidly degraded. In hypoxic environments, HIF-1α becomes stable and accumulates in the nucleus, where it activates genes involved in:
- Blood vessel formation
- Glucose metabolism
- Cell survival under stress
This allows cancer cells to adapt to oxygen deprivation while simultaneously promoting new vessel growth.
Key Pro-Angiogenic Factors
Tumor and stromal cells release multiple signaling molecules that stimulate endothelial cells. The most important include:
- VEGF (vascular endothelial growth factor) — the central regulator of tumor angiogenesis
- FGF (fibroblast growth factors) — stimulate endothelial proliferation
- PDGF (platelet-derived growth factor) — recruits pericytes and stabilizes vessels
- Angiopoietins (Ang-1 and Ang-2) — regulate vessel maturation and remodeling
These factors bind to receptors on endothelial cells, activating intracellular pathways that promote migration, proliferation, and survival.
The Angiogenic Switch in Tumor Progression
Early tumors may remain dormant and poorly vascularized for long periods. The transition to active blood vessel formation is known as the angiogenic switch.
This switch occurs when:
- Pro-angiogenic signals increase
- Anti-angiogenic factors decrease
- Inflammatory and stromal cells contribute additional growth factors
Once activated, angiogenesis enables rapid tumor expansion and supports further genetic evolution of cancer cells, making the disease more aggressive.
Abnormal Tumor Vasculature and Its Consequences
Structural Abnormalities of Tumor Blood Vessels
Unlike normal blood vessels, tumor vessels are:
- Irregular in shape and diameter
- Poorly organized and highly branched
- Deficient in pericyte coverage
- Highly permeable and leaky
These abnormalities result from uncontrolled angiogenic signaling and lack of proper vessel maturation mechanisms.
Effects on the Tumor Microenvironment
Abnormal vasculature leads to several harmful microenvironmental conditions:
- Persistent hypoxia, despite increased vessel number
- High interstitial fluid pressure, limiting nutrient and drug diffusion
- Acidic pH, due to altered metabolism and poor perfusion
- Chronic inflammation, promoting tumor progression
These conditions further stimulate angiogenesis, creating a vicious cycle that sustains tumor growth.
Impact on Metastasis and Therapy Response
Leaky and unstable vessels make it easier for tumor cells to:
- Enter the bloodstream (intravasation)
- Survive shear stress and immune attack
At the same time, abnormal blood flow reduces:
- Chemotherapy delivery
- Oxygen availability for radiotherapy effectiveness
This explains why highly vascularized tumors can still be resistant to treatment.
Targeting Angiogenesis in Cancer Therapy
Anti-Angiogenic Drugs and Strategies
Cancer therapies have been developed to disrupt tumor blood supply by targeting:
- VEGF directly (monoclonal antibodies)
- VEGF receptors (tyrosine kinase inhibitors)
- Other angiogenic pathways such as angiopoietins and integrins
These drugs are commonly combined with chemotherapy, targeted therapy, or immunotherapy to enhance treatment outcomes.
Vascular Normalization Concept
Rather than completely eliminating tumor blood vessels, some therapies aim to normalize them.
Vascular normalization can:
- Improve vessel structure and perfusion
- Reduce hypoxia
- Enhance drug and immune cell delivery
This approach supports combination therapy strategies, especially in immuno-oncology.
Limitations and Resistance to Anti-Angiogenic Therapy
Despite initial responses, many tumors develop resistance through:
- Activation of alternative angiogenic pathways
- Increased invasiveness and metastatic behavior
- Adaptation to hypoxic conditions
Therefore, anti-angiogenic therapy is rarely curative on its own and is most effective when used as part of multi-modal treatment strategies.
Conclusion
Angiogenesis is a fundamental biological process that becomes hijacked by tumors to support continuous growth and dissemination. Tumor-induced angiogenesis is driven primarily by hypoxia and sustained production of pro-angiogenic factors, resulting in abnormal and dysfunctional blood vessels. These vascular abnormalities shape the tumor microenvironment, promote metastasis, and reduce treatment effectiveness. Although anti-angiogenic therapies have improved outcomes in several cancers, resistance remains a major challenge. A deeper understanding of tumor vascular biology is essential for developing more effective and durable cancer treatments.
